
Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results
pharmafile | March 2, 2017 | News story | Research and Development | Herceptin, Perjeta, Roche
Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. The therapy improved invasive disease-free survival (iDFS) in those with HER2-positive early breast cancer (eBC) when administered post-surgery, compared to Herceptin and chemotherapy alone.
Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche, commented on the findings, saying: “These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer. We look forward to discussing these adjuvant results with global regulatory authorities.”
The combination therapy is already licensed as a pre-surgery solution for the disease in 75 countries, and the post-therapy treatment is currently under the FDA’s accelerated approval; Roche hopes this promising new data will aid the treatment’s path to full approval.
Gunter von Minckwitz, Study Coordinator from the Breast International Group and academic study partners, added: “APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease.”
The aggressive HER2-positive breast cancer is known for poor prognoses and affects around 20% of breast cancer sufferers.
Matt Fellows
Related Content

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …






